Javascript must be enabled to continue!
An MRTF-A–Sp1–PDE5 Axis Mediates Angiotensin-II-Induced Cardiomyocyte Hypertrophy
View through CrossRef
Cardiac hypertrophy is a critical intermediate step in the pathogenesis of heart failure. A myriad of signaling networks converge on cardiomyocytes to elicit hypertrophic growth in response to various injurious stimuli. In the present study, we investigated the cardiomyocyte-specific role of myocardin-related transcription factor A (MRTF-A) in angiotensin-II (Ang-II)-induced cardiac hypertrophy and the underlying mechanism. We report that conditional MRTF-A deletion in cardiomyocytes attenuated Ang-II-induced cardiac hypertrophy in mice. Similarly, MRTF-A knockdown or inhibition suppressed Ang-II-induced prohypertrophic response in cultured cardiomyocytes. Of note, Ang II treatment upregulated expression of phosphodiesterase 5 (PDE5), a known mediator of cardiac hypertrophy and heart failure, in cardiomyocytes, which was blocked by MRTF-A depletion or inhibition. Mechanistically, MRTF-A activated expression of specificity protein 1 (Sp1), which in turn bound to the PDE5 promoter and upregulated PDE5 transcription to promote hypertrophy of cardiomyocytes in response to Ang II stimulation. Therefore, our data unveil a novel MRTF-A–Sp1–PDE5 axis that mediates Ang-II-induced hypertrophic response in cardiomyocytes. Targeting this newly identified MRTF-A–Sp1–PDE5 axis may yield novel interventional solutions against heart failure.
Title: An MRTF-A–Sp1–PDE5 Axis Mediates Angiotensin-II-Induced Cardiomyocyte Hypertrophy
Description:
Cardiac hypertrophy is a critical intermediate step in the pathogenesis of heart failure.
A myriad of signaling networks converge on cardiomyocytes to elicit hypertrophic growth in response to various injurious stimuli.
In the present study, we investigated the cardiomyocyte-specific role of myocardin-related transcription factor A (MRTF-A) in angiotensin-II (Ang-II)-induced cardiac hypertrophy and the underlying mechanism.
We report that conditional MRTF-A deletion in cardiomyocytes attenuated Ang-II-induced cardiac hypertrophy in mice.
Similarly, MRTF-A knockdown or inhibition suppressed Ang-II-induced prohypertrophic response in cultured cardiomyocytes.
Of note, Ang II treatment upregulated expression of phosphodiesterase 5 (PDE5), a known mediator of cardiac hypertrophy and heart failure, in cardiomyocytes, which was blocked by MRTF-A depletion or inhibition.
Mechanistically, MRTF-A activated expression of specificity protein 1 (Sp1), which in turn bound to the PDE5 promoter and upregulated PDE5 transcription to promote hypertrophy of cardiomyocytes in response to Ang II stimulation.
Therefore, our data unveil a novel MRTF-A–Sp1–PDE5 axis that mediates Ang-II-induced hypertrophic response in cardiomyocytes.
Targeting this newly identified MRTF-A–Sp1–PDE5 axis may yield novel interventional solutions against heart failure.
Related Results
Protocatechuic acid attenuates isoproterenol-induced cardiac hypertrophy via downregulation of ROCK1–Sp1–PKCγ axis
Protocatechuic acid attenuates isoproterenol-induced cardiac hypertrophy via downregulation of ROCK1–Sp1–PKCγ axis
AbstractCardiac hypertrophy is an adaptive response of the myocardium to pressure overload or adrenergic agonists. Here, we investigated the protective effects and the regulatory m...
Pan-cancer analysis of Sp1 with a focus on immunological roles in gastric cancer
Pan-cancer analysis of Sp1 with a focus on immunological roles in gastric cancer
Abstract
Background
Sp1, a transcription factor, plays a pivotal role in tumorigenesis across diverse cancers. However, its comprehensive pan-cancer analyses and immunolog...
Discovery of Natural Phosphodiesterase 5 Inhibitors from Dalbergia cochinchinensis Pierre Leaves Using LC-QTOF-MS2
Discovery of Natural Phosphodiesterase 5 Inhibitors from Dalbergia cochinchinensis Pierre Leaves Using LC-QTOF-MS2
The imbalance of phosphodiesterase 5 (PDE5) enzyme in the male body, or excessive PDE5 enzyme levels, can occur due to factors such as aging, diseases (e.g., cardiovascular disease...
Development of angiotensin (1‐7) as an agent to accelerate dermal repair
Development of angiotensin (1‐7) as an agent to accelerate dermal repair
Angiotensin II has been shown to be a potent agent in the acceleration of wound repair. Angiotensin (1‐7), a fragment of angiotensin II that is not hypertensive, was found to be co...
Abstract 125: Modified Angiotensin II Has Lower Vasoconstrictive Effect Than Angiotensin II
Abstract 125: Modified Angiotensin II Has Lower Vasoconstrictive Effect Than Angiotensin II
Introduction:
The renin-angiotensin-aldosterone system (RAAS) is involved in the regulation of the blood pressure, water- and electrolyte balance. Pathophysiologically,...
GW24-e2217 AKAP150 anchored PKC to enhance cardiomyocyte damage in diabetes
GW24-e2217 AKAP150 anchored PKC to enhance cardiomyocyte damage in diabetes
Objectives
Cardiovascular disease is the main cause of death in patients with diabetes. It is reported that Protein kinase C signalling pathway plays a key role i...
(187) Efficiency and Safety of Combining Long-Acting and Short-Acting PDE5 Inhibitors
(187) Efficiency and Safety of Combining Long-Acting and Short-Acting PDE5 Inhibitors
Abstract
Introduction
Erectile dysfunction is a condition that affects many men worldwide, significantly impacting their quality...
PERK MEDIATED ENDOPLASMIC RETICULUM STRESS IS INVOLVED IN ANGIOTENSINIIINDUCED CARDIAC HYPERTROPHY
PERK MEDIATED ENDOPLASMIC RETICULUM STRESS IS INVOLVED IN ANGIOTENSINIIINDUCED CARDIAC HYPERTROPHY
Objectives
To investigate the role of protein kinase R-like ER kinase (PERK)-mediated endoplasmic reticulum stress (ERS) in angiotensin II, and to explore the rol...

